“Tonight, as President Trump and the Congress gather in the Capitol for the State of the Union address, we need real, tangible, bipartisan action on insulin affordability.

No one should go without the insulin they need to stay alive or the devices they need to dose it effectively. Important programs exist now to help with costs, but we need manufacturers, health plans, employers, and the government to make systemic changes to make insulin affordable to all.

Numerous proposals have been introduced in Congress that would lower the cost of insulin. We urge Congress and the President to work together to enact bipartisan legislation as soon as possible to address this issue. In addition, policymakers should prioritize renewing the Special Diabetes Program and protecting people with preexisting conditions.

Health care access is a top priority for JDRF, and we will continue to fight for coverage, affordability, and choice so that people with type 1 diabetes can lead healthier lives until there are cures for this disease.”

JDRF

New York, February 04, 2020

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF.